Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs

Michael Maes; Filip Goossens; Simon Scharpé; Joseph Calabrese; Roger Desnyder; Herbert Y. Meltzer

doi:10.1016/0165-1781(95)02698-V

Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs

Michael Maes^*, Filip Goossens, Simon Scharpé, Joseph Calabrese, Roger Desnyder, Herbert Y. Meltzer

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

158 Scopus citations

Abstract

The activity of prolyl endopeptidase (PEP), a serine proteinase, has been found to be significantly lower in the blood of patients with major depression than in normal volunteers. The present study investigates plasma PEP activity in 25 major depressed, 10 manic, and 14 schizophrenic subjects versus 30 normal volunteers. It also examines the effects of antidepressants, valproate, and neuroleptic drugs on plasma PEP activity. PEP activity was significantly lower in major depressed subjects than in normal volunteers and in patients with mania and schizophrenia. In depressed subjects, plasma PEP activity was significantly increased during treatment with antidepressant drugs, such as fluoxetine. Plasma PEP activity was significantly increased in manic and schizophrenic subjects compared with normal volunteers. In manic subjects, short-term treatment with valproate had a significant suppressive effect on PEP activity. No significant effects of neuroleptics on PEP activity could be found in the schizophrenic patients. The results support the hypothesis that lower PEP activity could play a role in the pathophysiology of major depression, while increased PEP activity may be related to psychotic conditions, such as mania and schizophrenia.

Original language	English (US)
Pages (from-to)	217-225
Number of pages	9
Journal	Psychiatry Research
Volume	58
Issue number	3
DOIs	https://doi.org/10.1016/0165-1781(95)02698-V
State	Published - Oct 16 1995

Funding

The researchr eportedw as supported,in part, by the Nationaal Fonds voor Wetenschappelijk Onderzoek (NFWO) and the IUAP Program, Belgium;U .S. Public Health Serviceg rantsM H-41684a nd GCRC MOlRR00080; grantsf rom the Elisabeth SeveranceP rentiss and John Pascal SawyerF oundationsa; nd the Michael Kaplen In-vestigatoAr ward (to M.M.). H.Y.M. is the recipient of a U.S. Public Health Service Research Career Scientist Award, MH-47808. The secretariaal ssistanceof Mrs. M. Maes is greatly appreciated.

Keywords

Fluoxetine
Neuroleptics
Peptidases
Peptides
Proteinases
Valproate

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0165-1781(95)02698-V

Cite this

@article{60988d3a45e6488186267ec9f204e84e,

title = "Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs",

abstract = "The activity of prolyl endopeptidase (PEP), a serine proteinase, has been found to be significantly lower in the blood of patients with major depression than in normal volunteers. The present study investigates plasma PEP activity in 25 major depressed, 10 manic, and 14 schizophrenic subjects versus 30 normal volunteers. It also examines the effects of antidepressants, valproate, and neuroleptic drugs on plasma PEP activity. PEP activity was significantly lower in major depressed subjects than in normal volunteers and in patients with mania and schizophrenia. In depressed subjects, plasma PEP activity was significantly increased during treatment with antidepressant drugs, such as fluoxetine. Plasma PEP activity was significantly increased in manic and schizophrenic subjects compared with normal volunteers. In manic subjects, short-term treatment with valproate had a significant suppressive effect on PEP activity. No significant effects of neuroleptics on PEP activity could be found in the schizophrenic patients. The results support the hypothesis that lower PEP activity could play a role in the pathophysiology of major depression, while increased PEP activity may be related to psychotic conditions, such as mania and schizophrenia.",

keywords = "Fluoxetine, Neuroleptics, Peptidases, Peptides, Proteinases, Valproate",

author = "Michael Maes and Filip Goossens and Simon Scharp{\'e} and Joseph Calabrese and Roger Desnyder and Meltzer, {Herbert Y.}",

note = "Funding Information: The researchr eportedw as supported,in part, by the Nationaal Fonds voor Wetenschappelijk Onderzoek (NFWO) and the IUAP Program, Belgium;U .S. Public Health Serviceg rantsM H-41684a nd GCRC MOlRR00080; grantsf rom the Elisabeth SeveranceP rentiss and John Pascal SawyerF oundationsa; nd the Michael Kaplen In-vestigatoAr ward (to M.M.). H.Y.M. is the recipient of a U.S. Public Health Service Research Career Scientist Award, MH-47808. The secretariaal ssistanceof Mrs. M. Maes is greatly appreciated.",

year = "1995",

month = oct,

day = "16",

doi = "10.1016/0165-1781(95)02698-V",

language = "English (US)",

volume = "58",

pages = "217--225",

journal = "Psychiatry Research",

issn = "0165-1781",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia

T2 - effects of antidepressants, mood stabilizers, and antipsychotic drugs

AU - Maes, Michael

AU - Goossens, Filip

AU - Scharpé, Simon

AU - Calabrese, Joseph

AU - Desnyder, Roger

AU - Meltzer, Herbert Y.

N1 - Funding Information: The researchr eportedw as supported,in part, by the Nationaal Fonds voor Wetenschappelijk Onderzoek (NFWO) and the IUAP Program, Belgium;U .S. Public Health Serviceg rantsM H-41684a nd GCRC MOlRR00080; grantsf rom the Elisabeth SeveranceP rentiss and John Pascal SawyerF oundationsa; nd the Michael Kaplen In-vestigatoAr ward (to M.M.). H.Y.M. is the recipient of a U.S. Public Health Service Research Career Scientist Award, MH-47808. The secretariaal ssistanceof Mrs. M. Maes is greatly appreciated.

PY - 1995/10/16

Y1 - 1995/10/16

N2 - The activity of prolyl endopeptidase (PEP), a serine proteinase, has been found to be significantly lower in the blood of patients with major depression than in normal volunteers. The present study investigates plasma PEP activity in 25 major depressed, 10 manic, and 14 schizophrenic subjects versus 30 normal volunteers. It also examines the effects of antidepressants, valproate, and neuroleptic drugs on plasma PEP activity. PEP activity was significantly lower in major depressed subjects than in normal volunteers and in patients with mania and schizophrenia. In depressed subjects, plasma PEP activity was significantly increased during treatment with antidepressant drugs, such as fluoxetine. Plasma PEP activity was significantly increased in manic and schizophrenic subjects compared with normal volunteers. In manic subjects, short-term treatment with valproate had a significant suppressive effect on PEP activity. No significant effects of neuroleptics on PEP activity could be found in the schizophrenic patients. The results support the hypothesis that lower PEP activity could play a role in the pathophysiology of major depression, while increased PEP activity may be related to psychotic conditions, such as mania and schizophrenia.

AB - The activity of prolyl endopeptidase (PEP), a serine proteinase, has been found to be significantly lower in the blood of patients with major depression than in normal volunteers. The present study investigates plasma PEP activity in 25 major depressed, 10 manic, and 14 schizophrenic subjects versus 30 normal volunteers. It also examines the effects of antidepressants, valproate, and neuroleptic drugs on plasma PEP activity. PEP activity was significantly lower in major depressed subjects than in normal volunteers and in patients with mania and schizophrenia. In depressed subjects, plasma PEP activity was significantly increased during treatment with antidepressant drugs, such as fluoxetine. Plasma PEP activity was significantly increased in manic and schizophrenic subjects compared with normal volunteers. In manic subjects, short-term treatment with valproate had a significant suppressive effect on PEP activity. No significant effects of neuroleptics on PEP activity could be found in the schizophrenic patients. The results support the hypothesis that lower PEP activity could play a role in the pathophysiology of major depression, while increased PEP activity may be related to psychotic conditions, such as mania and schizophrenia.

KW - Fluoxetine

KW - Neuroleptics

KW - Peptidases

KW - Peptides

KW - Proteinases

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=0028802506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028802506&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(95)02698-V

DO - 10.1016/0165-1781(95)02698-V

M3 - Article

C2 - 8570777

AN - SCOPUS:0028802506

SN - 0165-1781

VL - 58

SP - 217

EP - 225

JO - Psychiatry Research

JF - Psychiatry Research

IS - 3

ER -

Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this